Back

Risk stratification for a primary prevention ICD: Performance of the MADIT-ICD Benefit Score in contemporary real world patients

1 September 2024 (08:55 - 09:05)
Organised by: Logo
Congress Presentation Part of: 'Shocking' news on implantable cardioverter defibrillators Device Treatment ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Dillon J Dzikowicz

University of Rochester, Rochester (United States of America)

5 More presentations in this session

Presentation thumbnail
Insights from an international clinic survey on CIED patient management practices and perceptions
Doctor E. Martens (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Comparison of ICD implantation approach in children. The IChilDren study.
Professor V. Probst (Nantes, FR)
Abstract Slides Video
Presentation thumbnail
Risk for appropriate ICD intervention and complications in patients implanted after an out-hospital cardiac arrest compared to patients implanted for primary and other secondary prevention indication
Doctor E. Baldi (Pavia, IT)
Abstract Slides Video
Presentation thumbnail
Incidence of systolic heart failure and need for implantable cardiac defibrillators in patients with atrial fibrillation who had catheter ablation versus antiarrhythmic medical therapy
Doctor B. Ali (Cleveland, US)
Abstract Slides Video
Presentation thumbnail
Similar incidence of ICD-shocks in diabetic compared to non-diabetic patients receiving implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D)
Doctor S. Haxha (Lund, SE)
Abstract Slides Video

Access the full session

Session thumbnail
'Shocking' news on implantable cardioverter defibrillators
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 08:55 CET
You may be interested in
thumbnail
Congress Presentation
Mortality benefit of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: a real-world analysis
thumbnail
Congress Session
'Shocking' news on implantable cardioverter defibrillators
thumbnail
Congress Presentation
Primary prevention implantable cardioverter defibrillators are no longer indicated in non-ischaemic HFrEF: pro

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources